### Fludarabine

**Indication**
Chronic lymphocytic leukaemia or small lymphocytic lymphoma

**INN**
Fludarabine

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)

**EML status history**
First added in 2015 (TRS 994)

**Sex**
All

**Age**
Adolescents and adults

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions. Read more about patents.

**Tags**
- Cancer

**Wikipedia**
- Fludarabine

**DrugBank**
- Fludarabine

---

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, fludarabine was added to the complementary list of the EML for use in treatment protocols for chronic lymphocytic leukaemia. The relevant extract from TRS994 regarding the Expert Committee’s 2015 consideration of treatment protocols for chronic lymphocytic leukaemia is attached.

[Read more about patents.](#)